Scheduled end-of-Phase 2 meeting with the FDA for zervimesine (CT1812), allowing for discussion of results and proposed plans for a Phase 3 program in mild-to-moderate Alzheimer’s disease. Application ...
PURCHASE, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results